PHAT
Price
$8.23
Change
-$0.10 (-1.20%)
Updated
Jul 17, 04:46 PM (EDT)
Capitalization
581.55M
21 days until earnings call
URGN
Price
$15.15
Change
+$0.81 (+5.65%)
Updated
Jul 17, 03:03 PM (EDT)
Capitalization
661.18M
33 days until earnings call
Interact to see
Advertisement

PHAT vs URGN

Header iconPHAT vs URGN Comparison
Open Charts PHAT vs URGNBanner chart's image
Phathom Pharmaceuticals
Price$8.23
Change-$0.10 (-1.20%)
Volume$500
Capitalization581.55M
UroGen Pharma
Price$15.15
Change+$0.81 (+5.65%)
Volume$132
Capitalization661.18M
PHAT vs URGN Comparison Chart in %
Loading...
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PHAT vs. URGN commentary
Jul 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHAT is a Hold and URGN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 17, 2025
Stock price -- (PHAT: $8.33 vs. URGN: $14.34)
Brand notoriety: PHAT and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHAT: 33% vs. URGN: 21%
Market capitalization -- PHAT: $581.55M vs. URGN: $661.18M
PHAT [@Biotechnology] is valued at $581.55M. URGN’s [@Biotechnology] market capitalization is $661.18M. The market cap for tickers in the [@Biotechnology] industry ranges from $300.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHAT’s FA Score shows that 0 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • PHAT’s FA Score: 0 green, 5 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, both PHAT and URGN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHAT’s TA Score shows that 3 TA indicator(s) are bullish while URGN’s TA Score has 5 bullish TA indicator(s).

  • PHAT’s TA Score: 3 bullish, 4 bearish.
  • URGN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, URGN is a better buy in the short-term than PHAT.

Price Growth

PHAT (@Biotechnology) experienced а -11.10% price change this week, while URGN (@Biotechnology) price change was +3.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.99%. For the same industry, the average monthly price growth was +13.54%, and the average quarterly price growth was +38.97%.

Reported Earning Dates

PHAT is expected to report earnings on Nov 06, 2025.

URGN is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+1.99% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($661M) has a higher market cap than PHAT($582M). URGN YTD gains are higher at: 34.648 vs. PHAT (2.586). URGN has higher annual earnings (EBITDA): -119.79M vs. PHAT (-272.12M). PHAT has more cash in the bank: 212M vs. URGN (196M). URGN has less debt than PHAT: URGN (125M) vs PHAT (204M). URGN has higher revenues than PHAT: URGN (91.9M) vs PHAT (81.9M).
PHATURGNPHAT / URGN
Capitalization582M661M88%
EBITDA-272.12M-119.79M227%
Gain YTD2.58634.6487%
P/E RatioN/AN/A-
Revenue81.9M91.9M89%
Total Cash212M196M108%
Total Debt204M125M163%
FUNDAMENTALS RATINGS
URGN: Fundamental Ratings
URGN
OUTLOOK RATING
1..100
17
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
42
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PHATURGN
RSI
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 8 days ago
84%
Bullish Trend 8 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 16 days ago
87%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TVRFX77.83N/A
N/A
Thornburg Small/Mid Cap Core R3
IMCVX9.56N/A
N/A
Voya Multi-Manager Mid Cap Value I
JIGTX32.42N/A
N/A
JHancock International Growth R6
HWNIX14.15N/A
N/A
Hotchkis & Wiley International Value I
PTTEX81.31N/A
N/A
Putnam Global Technology R6

URGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with AIM. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then AIM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
+2.14%
AIM - URGN
39%
Loosely correlated
+0.68%
CYYNF - URGN
38%
Loosely correlated
N/A
CVAC - URGN
36%
Loosely correlated
+1.29%
PHAT - URGN
36%
Loosely correlated
-2.46%
ATXS - URGN
34%
Loosely correlated
+0.32%
More